000046225 000__ 01117cam\a22003975i\4500
000046225 001__ 46225
000046225 003__ SzGeWIPO
000046225 005__ 20230511164156.0
000046225 006__ m\\\\eo\\d\\\\\\\\
000046225 007__ cr bn |||m|||a
000046225 008__ 220602s2020\\\\nyu\\\\\o\\\\\000\0\eng\d
000046225 035__ $$a(OCoLC)1335038764
000046225 040__ $$aSzGeWIPO$$beng$$erda$$cSzGeWIPO$$dCaBNVSL
000046225 041__ $$aeng
000046225 24500 $$aShould COVID-19 treatment be patented? Rethinking the theoretical justification for the grant of pharmaceutical patent.
000046225 264_1 $$a[New York, NY] :$$bThomson Reuters,$$c2020
000046225 300__ $$a1 online resource
000046225 336__ $$atext$$2rdacontent
000046225 337__ $$acomputer$$2rdamedia
000046225 338__ $$aonline resource$$bcr$$2rdacarrier
000046225 4901_ $$aEuropean Intellectual Property Review,$$x0142-0461 ;$$vVolume 42, Issue 11
000046225 542__ $$fhttps://1.next.westlaw.com/Copyright
000046225 588__ $$aCrossref
000046225 590__ $$aPublished online: 2020
000046225 650_0 $$aIntellectual property.
000046225 650_0 $$aJurisprudence.
000046225 650_0 $$aPatents.
000046225 650_4 $$aCOVID-19 pandemic
000046225 7001_ $$aAdekola, Tolulope Anthony,$$eauthor.
000046225 7731_ $$tEuropean Intellectual Property Review
000046225 7731_ $$wEIPR
000046225 830_0 $$aEuropean Intellectual Property Review,$$vE.I.P.R. 2020, 42(11), 695-697
000046225 85641 $$uhttps://www.westlaw.com/Document/I11E4F1902A0211EB9EEEC5D73ED9FAC8/View/FullText.html?transitionType=Default&contextData=(sc.Default)&VR=3.0&RS=cblt1.0&sp=wlnintell-000$$yonline version
000046225 904__ $$aArticle
000046225 980__ $$aEIPR